NasdaqGS - Delayed Quote USD

AbCellera Biologics Inc. (ABCL)

2.3700
-0.0500
(-2.07%)
At close: June 5 at 4:00:01 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
23,114
28,833
38,025
485,424
375,203
Cost of Revenue
--
0
0
66,436
45,516
Gross Profit
--
28,833
38,025
418,988
329,687
Operating Expense
331,148
329,979
261,077
191,923
107,788
Operating Income
-308,034
-301,146
-223,052
227,065
221,899
Net Non Operating Interest Income Expense
36,123
38,473
42,247
16,079
3,330
Other Income Expense
61,279
62,278
6,776
-4,045
-6,080
Pretax Income
-210,632
-200,395
-174,029
239,099
219,149
Tax Provision
-42,764
-37,538
-27,631
80,580
65,685
Net Income Common Stockholders
-167,868
-162,857
-146,398
158,519
153,464
Diluted NI Available to Com Stockholders
-167,868
-162,857
-146,398
158,519
153,464
Basic EPS
-0.56
-0.55
-0.51
0.56
0.56
Diluted EPS
-0.56
-0.55
-0.51
0.50
0.48
Basic Average Shares
295,569.7220
294,327.5320
289,166.4860
285,056.6060
275,763.7450
Diluted Average Shares
295,569.7220
294,327.5320
289,166.4860
314,827.2550
318,294.2360
Total Operating Income as Reported
-322,532
-314,766
-237,207
216,511
204,413
Total Expenses
331,148
329,979
261,077
258,359
153,304
Net Income from Continuing & Discontinued Operation
-167,868
-162,857
-146,398
158,519
153,464
Normalized Income
-167,868
-162,857
-146,398
158,519
153,464
Interest Income
36,123
38,473
42,247
16,079
3,330
Interest Expense
--
--
--
4,045
5,225
Net Interest Income
36,123
38,473
42,247
16,079
3,330
EBIT
-308,034
-301,146
-223,052
227,065
221,899
EBITDA
-211,197
-204,148
-192,158
260,167
239,149
Reconciled Cost of Revenue
--
0
0
61,177
42,717
Reconciled Depreciation
96,837
96,998
30,894
33,102
17,250
Net Income from Continuing Operation Net Minority Interest
-167,868
-162,857
-146,398
158,519
153,464
Total Unusual Items Excluding Goodwill
--
--
--
--
-855
Total Unusual Items
--
--
--
--
-855
Normalized EBITDA
-211,197
-204,148
-192,158
260,167
239,149
Tax Rate for Calcs
0.0002
0.0002
0.0002
0.0003
0.0003
Tax Effect of Unusual Items
0
0
0
0
0
12/31/2021 - 12/11/2020

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

ATYR aTyr Pharma, Inc.
5.35
+4.09%
 
NTLA Intellia Therapeutics, Inc.
7.58
-1.17%
 
RXRX Recursion Pharmaceuticals, Inc.
4.5700
-6.92%
 
ACOG Alpha Cognition Inc.
9.67
+0.99%
 
BEAM Beam Therapeutics Inc.
17.00
-0.87%
 
ABSI Absci Corporation
2.8400
-0.35%
 
PRME Prime Medicine, Inc.
1.3600
+3.03%
 
DNA Ginkgo Bioworks Holdings, Inc.
7.23
-4.37%
 
VYGR Voyager Therapeutics, Inc.
3.3000
-0.60%
 
INAB IN8bio, Inc.
0.1201
-1.96%